Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-04-17
2007-04-17
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S014000, C435S025000, C514S866000
Reexamination Certificate
active
11069161
ABSTRACT:
The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.
REFERENCES:
patent: 4954445 (1990-09-01), Yoshihama et al.
patent: 5250416 (1993-10-01), Ohno et al.
patent: 5763496 (1998-06-01), Holland
patent: 5902831 (1999-05-01), Holland et al.
patent: 5955481 (1999-09-01), Ohara et al.
patent: 6090851 (2000-07-01), Dodd-o et al.
patent: 6218117 (2001-04-01), Herrnstadt et al.
patent: 6573291 (2003-06-01), Gronberg et al.
patent: 6878514 (2005-04-01), Morre et al.
patent: 6893833 (2005-05-01), Gronberg et al.
patent: 2001/0019832 (2001-09-01), Luthman
patent: 2002/0028768 (2002-03-01), Smith
patent: 0 551 662 (1993-07-01), None
patent: EP 1616576 (2006-01-01), None
patent: WO 99/12539 (1999-03-01), None
patent: WO 01/017533 (2001-03-01), None
Inoguchi T. et al. High Glucose Level . . . Diabetes 49(11)1939-1945, Nov. 2000.
Holland P. et al. Mechanism of Action of the Hypoglycemic Agent Diphenyleneiodonium. J of Biological Chemistry 248(17)6050-6059, 1973.
O'Donnell V. et al. Studies on the Inhibitory Mechanism of Idonium Compounds with Special Reference to Neutrophil NADPH Oxidase. Biochemistry J vol. 290, pp. 41-49, 1993.
Abo et al., “Reconstitution of Neutrophil NADPH Oxidase Activity in the Cell-free System by Four Components: p67-phox, p47-phox, p21racl, and Cytochrome b-245” Journal of Biological Chemistry, 267: 16767-70 (1992).
Babior, “The Respiratory Burst Oxidase”Advances in Enzymology&Related Areas of Molecular Biology65: 49-95 (1992).
Bayraktutan et al., “Expression of a Functional Neutrophil-type NADPH Oxidase in Cultured rat Coronary Microvascular Endothelial cells”Cardiovascular Research, 38: 256-62 (1998).
Blair et al., “Regulation of Glucose Transport and Glycogen Synthesis in L6 Muscle Cells During Oxidative Stress”Journal of Biological Chemistry274: 36293-9 (1999).
Brunmair et al., “Fenofibrate Impairs Rat Mitochondrial Function by Inhibition of Respiratory Complex 1”J. Pharmacol. Exp. Therapeutics311(1):109-14 (2004).
Davis et al., “Similarities in the Metabolism of Alloxan and Dehydroascorbate in Human Erythrocytes”Biochemical Pharmacology55: 1301-7 (1998).
Finkel et al., “Oxidants, Oxidative Stress and the Biology of Ageing”Nature408: 239-47 (2000).
Gatley, S.J. & Martin, J.L, “Some Aspects of the Pharmacology of Diphenyleneiodonium, a Bivalent Iodine Compound”Xenobiotica9: 539-546 (1979).
Holland et al. “Mechanism of Action of the Hypoglycemic Agent Diphenyleneiodonium”J. Biol. Chem.248: 6050-6056 (1973).
Hotta et al., “Pancreatic β Cell-Specific Expression of Thioredoxin, an Antioxidative and Antiapoptotic Protein, Prevents Autoimmune and Streptozotocin-induced Diabetes”Journal of Experimental Medicine188: 1445-51 (1998).
Inoguchi et al., “High Glucose Level and Free Fatty Acid Stimulate Reactive Oxygen Species Production Through Protein Kinase C-Dependent Activation of NAD(P)H Oxidase in Cultured Vascular Cells”Diabetes49: 1939-1945 (2000).
Jones et al., “Expression of Phagocyte NADPH Oxidase Components in Human Endothelial Cells”American Journal of Physiology271: H1626-34 (1996).
Knaus et al., “Purification and Charaterization of Rac2”Journal of Biological Chemistry, 267: 23575-82 (1992).
Kozlovsky et al., “Reactive Oxygen Species Activate Glucose Transport in L6 Myotubes”Free Radical Biology&Medicine23: 859-69 (1997).
Kozlovsky et al., “Transcriptional Activation of theGlut1Gene in Response to Oxidative Stress in L6 Myotubes”Journal of Biological Chemistry272: 33367-72 (1997).
Krieger-Brauer et al., “Insulin-Induced Activation of NADPH-dependent H2O2Generation in Human Adipocyte Plasma Membranes is Mediated by Gα12”Journal of Biological Chemistry, 272: 10135-43 (1997).
Laight et al., “Pro-oxidant Challengein vivoprovokes the onset of NIDDM in the Insulin Resistant Obese Zuker rat”British Journal of Pharmacology, 128: 269-71 (1999).
May et al., “The Insulin-like Effect of Hydrogen Peroxide on Pathways of Lipid Synthesis in Rat Adipocytes”Journal of Biological Chemistry254: 9017-21 (1979).
Mukherjee et al. , “Reduced NADPH Oxidase in Adipocyte Plasma Membrane and its Activation by Insulin”Arch. Biochem. Biophys184(1):69-76 (1977).
Paolisso et al., “Evidence for a Relationship Between Oxidative Stress and Insulin Active in Non-Insulin-Dependent (Type II) Diabetic Patients”Metabolism: Clinical&Experimental43: 1426-29 (1994).
Rudich et al., “Oxidant Stress Reduces Insulin Responsiveness 3T3-L1 Adipocytes”American Journal of Physiology272: E935-40 (1997).
Rudich et al., “Lipoic Acid Protects Against Oxidative Stress Induced Impairment in Insulin Stimulation of Protein Kinase B and Glucose Transport in 3T3-L1 Adipocytes”Diabetologia42: 949-57 (1999).
Rudkowski et al., “Auranofin Inhibits the Activation Pathways of Polymorphonuclear Leukocytes at Multiple Sites” Biochem. Pharmacol. 41(12):1921-29 (1991).
Salonen et al., “Increase Risk of Non-insulin Dependent Diabetes Mellitus at Low Plasma Vitamin E Concentrations: A Four Year Follow up Study in Men”BMJ311: 1124-27 (1995).
Segal et al., “The NADPH Oxidase of Phagocytic Leukocytes”Journal of Ocular Pharmacology&Therapeutics Annals of the New York Academy of Sciences832: 215-22 (1997).
Spector, “Review: Oxidative Stress and Disease” 16: 193-201 (2000).
Sumimoto et al., “Cytochromeb558, a Component of the Phagocyte NADPH Oxidase, is a Flavoprotein”Biochemical&Biophysical Research Communications, 186: 1368-75 (1992).
Tirosh et al., “Oxidative Stress Disrupts Insulin-Induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes”Journal of Biological Chemistry274: 10595-602 (1999).
Grönberg Alvar
Wikström Per
Fish & Richardson P.C.
Gitomer Ralph
Glucox AB
LandOfFree
Methods of treating insulin resistance with an inhibitor of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating insulin resistance with an inhibitor of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating insulin resistance with an inhibitor of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734847